InnoCom makes investments into worthy Life Science companies, providing:
- Investment opportunities in cutting edge technologies
- Access to early commercialization for life Science innovators
- Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing
- Industry networking to access revenue at 2-3 years following pre-clinical trials
- Providing revenue and/or takeout at 7 years end of clinical trials
- Business Counsel and advice to the company management team
- Corporate Officer participation, setting up strong Systems, Procedures, and Protocols
- Board of Directors Membership, building strong Corporate Governance
- Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years
- Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years
- Enhancing the delivery of health solutions to the patients who need them